



(12) Translation of  
European patent specification

(11) NO/EP 2794628 B1

NORWAY

(19) NO  
(51) Int Cl.  
**C07H 19/10 (2006.01)**  
**A61K 31/7068 (2006.01)**  
**A61K 31/7072 (2006.01)**  
**C07H 19/20 (2006.01)**

**Norwegian Industrial Property Office**


---

|      |                                                                      |                                                                                                                                                                                                                                                                                             |
|------|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (21) | Translation Published                                                | 2017.08.28                                                                                                                                                                                                                                                                                  |
| (80) | Date of The European Patent Office Publication of the Granted Patent | 2017.03.29                                                                                                                                                                                                                                                                                  |
| (86) | European Application Nr.                                             | 12808791.3                                                                                                                                                                                                                                                                                  |
| (86) | European Filing Date                                                 | 2012.12.17                                                                                                                                                                                                                                                                                  |
| (87) | The European Application's Publication Date                          | 2014.10.29                                                                                                                                                                                                                                                                                  |
| (30) | Priority                                                             | 2011.12.20, US, 201161577712 P                                                                                                                                                                                                                                                              |
| (84) | Designated Contracting States:                                       | AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR                                                                                                                                                                           |
| (73) | Proprietor                                                           | Riboscience LLC, 3901 Laguna Avenue, Palo Alto, CA 94306, US-USA                                                                                                                                                                                                                            |
| (72) | Inventor                                                             | SMITH, Mark, 333 Harrison Street, No. 363, San Francisco, CA 94105, US-USA<br>TALAMAS, Francisco Xavier, 23 Westmount Drive, Livingston, NJ 07039, US-USA<br>ZHANG, Jing, 161 Carlton Drive, Parsippany, NJ 07054, US-USA<br>ZHANG, Zhuming, 59 Wesley Road, Hillsborough, NJ 08844, US-USA |
| (74) | Agent or Attorney                                                    | Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge                                                                                                                                                                                                                                       |

---

|      |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (54) | Title             | <b>4'-AZIDO-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION</b>                                                                                                                                                                                                                                                                                                                                              |
| (56) | References Cited: | WO-A2-02/100415<br>DAVID B. SMITH ET AL: "The Design, Synthesis, and Antiviral Activity of Monofluoro and Difluoro Analogues of 4'-Azidocytidine against Hepatitis C Virus Replication: The Discovery of 4'-Azido-2'-deoxy-2'-fluorocytidine and 4'-Azido-2'-dideoxy-2',2'-difluorocytidine ", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 9, 14 May 2009 (2009-05-14), pages 2971-2978, XP055054142, ISSN: 0022-2623, DOI: 10.1021/jm801595c |

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**Patentkrav****1. Forbindelse med formel I****I**

5 hvori:

$R^1$  er H,  $C_{1-7}$ -haloalkyl eller aryl, hvori aryl er fenyl eller naftyl, eventuelt substituert med ett eller flere  $C_{1-7}$ -alkyl,  $C_{2-7}$ -alkenyl,  $C_{2-7}$ -alkynyl,  $C_{1-7}$ -alkoksy, halo,  $C_{1-7}$ -haloalkyl,  $-N(R^{1a})_2$ , acylamino,  $-SO_2N(R^{1a})_2$ ,  $-COR^{1b}$ ,  $-SO_2(R^{1c})$ ,  $-NHSO_2(R^{1c})$ , nitro eller cyano;

10 hver  $R^{1a}$  uavhengig er H eller  $C_{1-7}$ -alkyl;

hver  $R^{1b}$  uavhengig er  $-OR^{1a}$  eller  $-N(R^{1a})_2$ ;

hver  $R^{1c}$  er  $C_{1-7}$ -alkyl;


$R^{2a}$  og  $R^{2b}$  uavhengig er H eller  $C_{1-7}$ -alkyl;

$R^3$  er  $C_{1-7}$ -alkyl, fenyl eller fenyl  $C_{1-7}$ -alkyl;

15  $R^4$  er H,  $C_{1-7}$ -alkyl, eller  $R^{2b}$  og  $R^4$  sammen danner  $(CH_2)_3$ ;

$R^5$  er H,  $C(=O)R^{1c}$ ,  $C(=O)R^{1b}$ ,  $P(=O)(OR^1)(OR^{1a})$  eller  $P(=O)(OR^1)(NR^4R^7)$ ; og

$R^6$  er



eller et farmasøytisk akseptabelt salt derav.

20

**2.** Forbindelsen ifølge krav 1, hvori  $R^4$  er H.

**3.** Forbindelsen ifølge krav 2, hvori  $R^1$  er naftyl eller fenyl.

25

**4.** Forbindelsen ifølge krav 3, hvori  $R^{2a}$  er H.

**5.** Forbindelsen ifølge krav 4, hvori  $R^{2b}$  er metyl.


**6.** Forbindelsen ifølge krav 5, hvori  $R^3$  er isopropyl, etyl eller benzyl.

7. Forbindelsen ifølge krav 6, hvori  $R^5$  er H.


8. Forbindelsen ifølge krav 6, hvori  $R^5$  er  $C(=O)R^{1c}$ .

9. Forbindelsen ifølge krav 8, hvori  $R^{1c}$  er etyl.

10. Forbindelsen ifølge krav 7, hvori  $R^6$  er



11. Forbindelsen ifølge krav 7, hvori  $R^6$  er



12. Forbindelsen ifølge krav 1, hvori forbindelsen er valgt fra gruppen bestående av:

(S)-2-2-[(2R,3S,4S,5R)-2-Azido-5-(2,4-diokso-3,4-dihydro-2H-pyrimidin-1-yl)-3-fluor-4-hydroksy-tetrahydro-furan-2-ylmetoksy]-fenoksy-fosforylamino}-propansyreisopropylester;

(S)-2-2-[(2R,3S,4S,5R)-2-Azido-5-(2,4-diokso-3,4-dihydro-2H-pyrimidin-1-yl)-3-fluor-4-hydroksy-tetrahydro-furan-2-ylmetoksy]-fenoksy-fosforylamino}-propansyreetyler;

(S)-2-2-[(2R,3S,4S,5R)-2-Azido-5-(2,4-diokso-3,4-dihydro-2H-pyrimidin-1-yl)-3-fluor-4-hydroksy-tetrahydro-furan-2-ylmetoksy]-(naftalen-1-yloksy)-fosforylamino]-propansyreetyler;

(S)-2-2-[(2R,3S,4S,5R)-5-(4-Amino-2-okso-2H-pyrimidin-1-yl)-2-azido-3-fluor-4-hydroksy-tetrahydro-furan-2-ylmetoksy]-(naftalen-1-yloksy)-fosforylamino]-propansyreisopropylester;

(S)-2-2-[(2R,3S,4S,5R)-5-(4-Amino-2-okso-2H-pyrimidin-1-yl)-2-azido-3-fluor-4-hydroksy-tetrahydro-furan-2-ylmetoksy]-(naftalen-1-yloksy)-fosforylamino]-propansyrebenzylester;

(S)-2-[[[(2R,3S,4S,5R)-5-(4-Amino-2-okso-2*H*-pyrimidin-1-yl)-2-azido-3-fluor-4-hydroksy-tetrahydro-furan-2-ylmetoksy]-(naftalen-1-yloksy)-fosforylamino]-propansyreetyler;

5 (S)-2-[[[(2R,3S,4S,5R)-5-(4-Amino-2-okso-2*H*-pyrimidin-1-yl)-2-azido-3-fluor-4-hydroksy-tetrahydro-furan-2-ylmetoksy]-fenoksy-fosforylamino]-propansyreisopropylester;

(S)-2-[[[(2R,3S,4S,5R)-5-(4-Amino-2-okso-2*H*-pyrimidin-1-yl)-2-azido-3-fluor-4-hydroksy-tetrahydro-furan-2-ylmetoksy]-hydroksy-fosforylamino]-propansyreisopropylester; og

10 (S)-2-[[[(2R,3S,4S,5R)-5-(4-Amino-2-okso-2*H*-pyrimidin-1-yl)-2-azido-3-fluor-4-propionylloksy-tetrahydro-furan-2-ylmetoksy]-(naftalen-1-yloksy)-fosforylamino]-propansyreisopropylester.

15 **13.** Forbindelse ifølge et hvilket som helst av kravene 1-12 for anvendelse i behandling eller profylakse av hepatitt C-virus (HCV-)infeksjon.

**14.** Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1-12 og terapeutisk inerte bærere.